Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for prevention of acute graft-versus-host disease after HLA-matched allogeneic hematopoietic progenitor cell transplantation
ACTRN12614000266662Phase 3Recruiting
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in graft-versus-host disease (GVHD) comparing Tocilizumab + standard transplant immunosuppression with Placebo + standard transplant immunosuppression (2 arms). Primary endpoint: Incidence of grade II-IV acute graft-versus-host disease. Started Apr 2014; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ACTRN12614000266662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000266662.